Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by BlossomHill Therapeutics, Inc.

News headline image
BlossomHill Therapeutics Announces Upcoming Presentation for BH-30236, an Oral Macrocyclic CLK Inhibitor, at the 68th American Society of Hematology (ASH) Annual Meeting
From BlossomHill Therapeutics, Inc.
Via GlobeNewswire
Tickers BLSM
News headline image
BlossomHill Therapeutics to Present at Guggenheim’s 3rd Annual Healthcare Innovations Conference
From BlossomHill Therapeutics, Inc.
Via GlobeNewswire
Tickers BLSM
News headline image
BlossomHill Therapeutics Announces Collaboration with Foundation Medicine to Develop First Companion Diagnostic for BH-30643 in EGFR C797S Mutated Non-Small Cell Lung Cancer
From BlossomHill Therapeutics, Inc.
Via GlobeNewswire
Tickers BLSM
News headline image
BlossomHill Therapeutics Presents Preclinical Data on Novel Pan-KRAS Inhibitor, BH-501284, at the AACR Conference on Pancreatic Cancer
From BlossomHill Therapeutics, Inc.
Via GlobeNewswire
Tickers BLSM
News headline image
BlossomHill Therapeutics Reports Second Quarter 2026 Financial Results
From BlossomHill Therapeutics, Inc.
Via GlobeNewswire
Tickers BLSM
News headline image
BlossomHill Therapeutics Presents Updated Data from Ongoing Phase 1/2 SOLARA Trial Demonstrating Encouraging Anti-Tumor Activity of OMNI-EGFR™ Inhibitor BH-30643 in EGFR C797S-Positive NSCLC at IASLC 2026 World Conference on Lung Cancer
From BlossomHill Therapeutics, Inc.
Via GlobeNewswire
Tickers BLSM
News headline image
BlossomHill Therapeutics to Present at the 8th Annual RAS-Targeted Drug Development Summit & H.C. Wainwright 28th Annual Global Investment Conference
From BlossomHill Therapeutics, Inc.
Via GlobeNewswire
Tickers BLSM
News headline image
BlossomHill Therapeutics to Present Updated Data from Ongoing Phase 1/2 SOLARA Trial of its Macrocyclic OMNI-EGFR™ Inhibitor, BH-30643, in EGFR-mutant NSCLC at the 2026 World Conference on Lung Cancer
From BlossomHill Therapeutics, Inc.
Via GlobeNewswire
Tickers BLSM
News headline image
BlossomHill Therapeutics Announces FDA Fast Track Designation for BH-30643, a Macrocyclic OMNI-EGFR™ Inhibitor for the Treatment of Advanced EGFR C797S-positive NSCLC
From BlossomHill Therapeutics, Inc.
Via GlobeNewswire
Tickers BLSM
News headline image
BlossomHill Therapeutics Announces Pricing of Upsized $150 Million Initial Public Offering
From BlossomHill Therapeutics, Inc.
Via GlobeNewswire
News headline image
BlossomHill Therapeutics Presents Initial Clinical Data from Dose Escalation in Ongoing Phase 1/1b Trial of Novel Macrocyclic CLK Inhibitor, BH-30236, in Patients with R/R AML or HR-MDS at EHA 2026
From BlossomHill Therapeutics, Inc.
Via GlobeNewswire
News headline image
BlossomHill Therapeutics to Present Preliminary Results From Phase 1 Dose Escalation/Backfill Cohorts in Phase 1/2 SOLARA Trial of OMNI-EGFR Inhibitor, BH-30643, in Advanced EGFR-mutant NSCLC at the 2026 ASCO Annual Meeting
From BlossomHill Therapeutics, Inc.
Via GlobeNewswire
News headline image
BlossomHill Therapeutics Expands Board of Directors with the Appointments of Sheila Gujrathi, M.D., and John Schmid
From BlossomHill Therapeutics, Inc.
Via GlobeNewswire
News headline image
BlossomHill Therapeutics to Present Initial Clinical Dose Escalation Data from the Phase 1/1b Trial of BH-30236 in Patients with R/R AML or HR-MDS at EHA2026
From BlossomHill Therapeutics, Inc.
Via GlobeNewswire
News headline image
BlossomHill Therapeutics Presents First Preclinical Data from New Pan-KRAS Inhibitor Program Built on a Novel Chemical Scaffold During Mini Symposium at AACR 2026
From BlossomHill Therapeutics, Inc.
Via GlobeNewswire
News headline image
BlossomHill Therapeutics Unveils New Pan-KRAS Inhibitor Programs and Announces Upcoming Presentations at AACR Annual Meeting 2026
From BlossomHill Therapeutics, Inc.
Via GlobeNewswire
News headline image
BlossomHill Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12
From BlossomHill Therapeutics, Inc.
Via GlobeNewswire
News headline image
BlossomHill Therapeutics Announces $84 Million Financing to Accelerate Clinical-Stage Pipeline of Intelligently Designed Cancer Medicines Including First-in-class Macrocyclic OMNI-EGFRTM Inhibitor for NSCLC
From BlossomHill Therapeutics, Inc.
Via GlobeNewswire
News headline image
BlossomHill Therapeutics to Present at the 67th American Society of Hematology (ASH) Annual Meeting on Design of Phase 1/1b Study of BH-30236, an Oral Macrocyclic CLK Inhibitor, in R/R AML or HR-MDS
From BlossomHill Therapeutics, Inc.
Via GlobeNewswire
News headline image
BlossomHill Therapeutics Presents Preliminary Findings from Phase 1/2 SOLARA Trial of BH-30643 in EGFR-mutant NSCLC at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
From BlossomHill Therapeutics, Inc.
Via GlobeNewswire
News headline image
BlossomHill Therapeutics Announces Upcoming Poster Presentation on Phase 1/2 SOLARA Trial of BH-30643, a First-in-class, Macrocyclic OMNI-EGFR™ Inhibitor, at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
From BlossomHill Therapeutics, Inc.
Via GlobeNewswire
News headline image
BlossomHill Therapeutics Announces First Patient Dosed in Expansion Cohorts of the Phase 1/2 SOLARA Trial, Evaluating BH-30643 in Advanced EGFR-mutant Non-Small Cell Lung Cancer
From BlossomHill Therapeutics, Inc.
Via GlobeNewswire
News headline image
BlossomHill Therapeutics Appoints Jason Keyes as Chief Financial Officer and Executive Vice President
From BlossomHill Therapeutics, Inc.
Via GlobeNewswire
News headline image
BlossomHill Therapeutics to Present the Design and Discovery of BH-30643, the Company’s OMNI-EGFR™ Inhibitor, at the 2025 AACR Annual Meeting
From BlossomHill Therapeutics, Inc.
Via Business Wire
News headline image
BlossomHill Therapeutics Doses Patients in the First Cohort of the Phase 1/2 SOLARA Clinical Trial of BH-30643 for EGFR- and HER2-Mutated Non-Small Cell Lung Cancer
From BlossomHill Therapeutics, Inc.
Via Business Wire
News headline image
BlossomHill Therapeutics Appoints Geoff Oxnard, M.D., as Chief Medical Officer and Executive Vice President
From BlossomHill Therapeutics, Inc.
Via Business Wire
News headline image
BlossomHill Therapeutics Chief Executive Officer, Jingrong Jean Cui, Ph.D., Elected to the National Academy of Engineering
From BlossomHill Therapeutics, Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.